Skip to main content

Advertisement

Log in

The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents

  • Original Paper
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Fabry disease (FD) is a debilitating progressive multisystem X-linked lysosomal storage disorder. It was generally believed that the disease affects only adult males. Through systematic pedigree analysis, we identified 35 paediatric FD patients (age 1 to 21 years, mean 12.6 years) in 25 families. Predominant signs in this cohort were: acroparesthesia, hypohidrosis, and cornea verticillata. Neurological and psychological changes, such as tinnitus, recurrent vertigo, headache, diminished level of activity, fatigue, and depression were often observed. Angiokeratoma and gastrointestinal symptoms were frequent. Some patients also showed cardiac abnormalities. Six children and adolescents (three males and three females) over 14 years of age had renal involvement (all with proteinuria, one male had a decreased creatinine clearance of 62 ml/min). No males, but three females (1.5, 4 and 9 years of age), were free of signs and symptoms. Males (n=15, age 1 to 21 years, mean 12.4 years) and females (n=20, age 1.5 to 20 years, mean 12.7 years) showed comparable disease severity. However, the clinical courses demonstrated a wide intra- and interfamilial variability and tended to be more heterogeneous in the girls. Female patients are frequently affected at an early age, not much differently than males. They should be carefully examined because most carriers are symptomatic. Conclusion: Fabry disease usually becomes clinically manifest in childhood. Renal involvement can begin in adolescence. The diagnosis is made following a high level of suspicion or systematic pedigree analysis. It is crucial for paediatric Fabry disease patients to have early access to optimal supportive symptomatic management. Enzyme replacement therapy has shown promising effectiveness in adults. Considering its widespread therapeutic and potential preventive benefits, enzyme replacement therapy should be initiated at an early stage, prior to the onset of irreversible complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.

Similar content being viewed by others

Abbreviations

FD :

Fabry disease

GALA :

α-galactosidase A

Gb 3 :

globotriaosylceramide

References

  1. Argoff CE, Barton NW, Brady RO, Ziessman HA (1998) Gastrointestinal symptoms and delayed gastric emptying in Fabry's disease: response to metoclopramide. Nucl Med Commun 19: 887–891

    CAS  PubMed  Google Scholar 

  2. Birklein F (2002) Mechanism-based treatment principles of neuropathic pain. Fortschr Neurol Psychiatr 70: 88–94

    Article  CAS  PubMed  Google Scholar 

  3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L (1967) Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 276: 1163–1167

    CAS  PubMed  Google Scholar 

  4. Cable WJ, Dvorak AM, Osage JE, Kolodny EH (1982) Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 32: 347–353

    CAS  PubMed  Google Scholar 

  5. El-Shahawy MA, Mesa C, Koss M, Campese VM (1996) A 19-year-old female with fever, acroparesthesia, and progressive deterioration of renal function. Am J Nephrol 16: 417–424

    CAS  Google Scholar 

  6. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, Caplan L, Linthorst GE, Desnick RJ (2001) Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345: 9–16

    Google Scholar 

  7. Epinette WW, Norins AL, Drew AL, Zeman W, Patel V (1973) Angiokeratoma corporis diffusum with α-L-fucosidase deficiency. Arch Dermatol 107: 754–757

    Article  CAS  PubMed  Google Scholar 

  8. Gehler J, Sewell AC, Becker C, Hartmann J, Spranger J (1981) Clinical and biochemical delineation of aspartyl-glycosaminuria as observed in two members of an Italian family. Helv Paediatr Acta 36: 179–189

    CAS  PubMed  Google Scholar 

  9. Hilz MJ, Stemper B, Kolodny EH (2000) Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 84: 361–365

    Article  CAS  PubMed  Google Scholar 

  10. Inagaki M, Ohno K, Ohta S, Sakuraba H, Takeshita K (1990) Relief of chronic burning pain in Fabry disease with neurotropin. Pediatr Neurol 6: 211–213

    Article  CAS  PubMed  Google Scholar 

  11. Kampmann C, Baehner F, Whybra C, Martin C, Wiethoff CM, Ries M, Gal A, Beck M (2002) Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 40: 1668–1674

    Article  PubMed  Google Scholar 

  12. Kanzaki T, Yokota M, Mizuno N, Matsumoto Y, Hirabayashi Y (1989) Novel lysosomal glycoaminoacid storage disease with angiokeratoma corporis diffusum. Lancet 1: 875–877

    CAS  PubMed  Google Scholar 

  13. Lao LM, Kumakiri M, Mima H, Kuwahara H, Ishida H, Ishiguro K, Fujita T, Ueda K (1998) The ultrastructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohidrosis. J Dermatol Sci 18: 109–117

    Article  CAS  PubMed  Google Scholar 

  14. Lenoir G, Rivron M, Gubler MC, Dufier JL, Tome FS, Guivarch M (1977) Fabry's disease. Carbamazepine therapy in acrodyniform syndrome. Arch Fr Pediatr 34: 704–716

    CAS  PubMed  Google Scholar 

  15. Lockman LA, Hunninghake DB, Krivit W, Desnick RJ (1973) Relief of pain of Fabry's disease by diphenylhydantoin. Neurology 23: 871–875

    CAS  PubMed  Google Scholar 

  16. Luciano CA, Russell JW, Banerjee TK, Quirk JM, Scott LJ, Dambrosia JM, Barton NW, Schiffmann R (2002) Physiological characterization of neuropathy in Fabry's disease. Muscle Nerve 26: 622–629

    Article  PubMed  Google Scholar 

  17. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38: 769–775

    Article  CAS  PubMed  Google Scholar 

  18. MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 38: 750–760

    Article  CAS  PubMed  Google Scholar 

  19. Mayes JS, Scheerer JB, Sifers RN, Donaldson ML (1981) Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112: 247–251

    Article  CAS  PubMed  Google Scholar 

  20. Miyatake T, Atsumi T, Obayashi T, Mizuno Y, Ando S, Ariga T, Matsui-Nakamura K, Yamada T (1979) Adult type neuronal storage disease with neuraminidase deficiency. Ann Neurol 6: 232–244

    CAS  PubMed  Google Scholar 

  21. O'Brien BD, Shnitka TK, McDougall R, Walker K, Costopoulos L, Lentle B, Anholt L, Freeman H, Thomson AB (1982) Pathophysiologic and ultrastructural basis for intestinal symptoms in Fabry's disease. Gastroenterology 82: 957–962

    CAS  PubMed  Google Scholar 

  22. Qin G, Takenaka T, Telsch K, Kelley L, Howard T, Levade T, Deans R, Howard BH, Malech HL, Brady RO, Medin JA (2001) Preselective gene therapy for Fabry disease. Proc Natl Acad Sci USA 98: 3428–3433

    Article  CAS  PubMed  Google Scholar 

  23. Ries M, Wendrich K, Whybra C, Kampmann C, Gal A, Beck M (2001) Angiokeratoma and pain, but not Fabry's disease: considerations for differential diagnosis. Contrib Nephrol 136: 256–259

    PubMed  Google Scholar 

  24. Ries M, Mengel M, Kutschke G, Kim KS, Birklein F, Krummenauer F, Beck M (2003) Use of gabapentin to reduce chronic neuropathic pain in Fabry disease. J Inherit Metab Dis 26: 413–414

    CAS  Google Scholar 

  25. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, Balow JE, Brady RO (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285: 2743–2749

    Article  CAS  PubMed  Google Scholar 

  26. Wenger DA, Sattler M, Mueller OT, Myers GG, Schneiman RS, Nixon GW (1980) Adult GM1 gangliosidosis: clinical and biochemical studies on two patients and comparison to other patients called variant or adult GM1 gangliosidosis. Clin Genet 17: 323–334

    CAS  PubMed  Google Scholar 

  27. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, Bruhl K, Gal A, Bunge S, Beck M (2001) Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 24: 715–724

    Article  CAS  Google Scholar 

  28. Whybra C, Wendrich K, Miebach E, Baehner F, Ries M, Schmiedeskamp C, Kampmann C, Beck M (2001) Fabry disease: Mainz Severity Score Index (MSSI). J Inherit Metab Dis 24[Suppl.2]: 133–134

    Google Scholar 

  29. Yuen NW, Lam CW, Chow TC, Chiu MC (1997) A characteristic dissection microscopy appearance of a renal biopsy of a Fabry heterozygote. Nephron 77: 354–356

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Markus Ries.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ries, M., Ramaswami, U., Parini, R. et al. The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents. Eur J Pediatr 162, 767–772 (2003). https://doi.org/10.1007/s00431-003-1299-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00431-003-1299-3

Keywords

Navigation